Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 22Breast Neoplasms 3Triple Negative Breast Neoplasms 2Prostate Adenocarcinoma 2Neoplasm Metastasis 2Stage I Prostate Adenocarcinoma AJCC v7 1Salivary Gland Neoplasms 1Primary Dysautonomias 1Paget Disease, Extramammary 1PSA Level Greater Than Two 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Kidney Diseases 1Hypertension 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

pembrolizumab 69Nivolumab 67cabozantinib 45Ipilimumab 36Specimen Handling 32Magnetic Resonance Spectroscopy 32lenvatinib 26Axitinib 25belzutifan 21Sunitinib 17Biopsy 15Radiosurgery 14CTLA-4 Antigen 13atezolizumab 12Everolimus 10pazopanib 8fludarabine 8avelumab 8Bevacizumab 8toripalimab 7cemiplimab 7Nephrectomy 7Immunoglobulin G 7Cyclophosphamide 7aldesleukin 6Standard of Care 6Radiotherapy 6Blood Specimen Collection 6spartalizumab 5palbociclib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × bicalutamide × 1 year × Clear all
NCT06222593 2026-04-01

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

State University of New York at Buffalo

Phase 1/2 Recruiting
28 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡